PSNLPersonalis, Inc.

Nasdaq personalis.com


$ 1.26 $ 0.01 (1.2 %)    

Friday, 26-Apr-2024 15:59:50 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 1.265
$ 1.26
$ 1.26 x 400
$ 5.00 x 100
$ 1.26 - $ 1.28
$ 0.89 - $ 2.60
49,108
na
60.94M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-03-2023 03-31-2023 10-Q
5 02-23-2023 12-31-2022 10-K
6 11-02-2022 09-30-2022 10-Q
7 08-03-2022 06-30-2022 10-Q
8 05-04-2022 03-31-2022 10-Q
9 02-24-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-04-2021 06-30-2021 10-Q
12 05-05-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-25-2020 12-31-2019 10-K
18 11-13-2019 09-30-2019 10-Q
19 08-13-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cathie-woods-ark-laps-up-33m-worth-of-tesla-as-stock-falls-for-3rd-straight-session-sheds-shares-of-this-sports-betting-company

Tesla found favor with bullish fund manager Cathie Wood, as her firm lapped up Tesla shares following its 10% slide over three ...

 needham-reiterates-buy-on-personalis-maintains-35-price-target

Needham analyst Mike Matson reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $3.5 price target.

 personalis-announces-publication-validating-next-personal-test-for-ultra-sensitive-mrd-detection-and-cancer-treatment-response-monitoring

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive ...

 cathie-woods-ark-invest-sells-another-tranche-of-block-shares-even-as-bitcoin-price-stages-a-recovery

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CR...

 cathie-woods-ark-invest-isnt-done-selling-shares-of-jack-dorsey-led-block-yet--sheds-75m-worth-of-stock-as-bitcoin-price-drops

On Tuesday, Cathie Wood-led Ark Invest offloaded a significant amount of Block Inc (NYSE:SQ) shares amidst a downturn in Bitcoi...

 cathie-wood-sells-1315m-worth-of-coinbase-shares-amid-bitcoin-flirting-with-all-time-high-levels--shops-for-palantir-stock-instead

On Thursday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc (NASDAQ:COIN) and Palantir Techn...

 lumen-technologies-and-2-other-stocks-under-2-insiders-are-buying

The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confi...

 needham-maintains-buy-on-personalis-raises-price-target-to-35

Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $2.3 to $3.5.

 personalis-q4-earnings-insights
Personalis: Q4 Earnings Insights
02/28/2024 21:10:29

 personalis-q4-2023-gaap-eps-054-misses-047-estimate-sales-1968m-miss-1974m-estimate

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.47) ...

 earnings-scheduled-for-february-28-2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

 personalis-and-clearnote-health-announce-partnership

Personalis to offer ClearNote's patented Epigenomic Platform to its biopharmaceutical partners

 needham-reiterates-buy-on-personalis-maintains-23-price-target

Needham analyst Mike Matson reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $2.3 price target.

 personalis-reports-preliminary-q4-and-fy23-revenue-and-cash-balance-sees-q4-revenue-197m-vs-1962m-est-sees-fy23-revenue-735m-vs-7341m-est

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary reve...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION